BIIB
Update on Regulatory Submission for Aducanumab in the European Union
Friday, April 22, 2022 BiopharmaWatch Research 1 min read Key Takeaway: Update on Regulatory Submission for Aducanumab in the European Union
Price reaction · baseline $218.4 (2022-04-21 close) · hit after-hours · clean, no other BIIB news in the window
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis
Full Press Release Details
Update on Regulatory Submission for Aducanumab in the European Union.